Revealed: the AI headband that relieves nasal allergy symptoms and that shoppers say 'literally helps me breathe' (and it's FDA-approved)
Allergies can absolutely demolish your day. One minute you're breathing in the fresh, clean air, and the next you're struggling to keep your head up because you can't stop sneezing, sniffling, and practically weeping.
It's enough to throw anyone off their game, which is why the SoundHealth SONU Band has more than caught our attention. This truly revolutionary headband is designed to provide a drug-free solution to your allergy woes, offering relief from congestion, a runny nose, and itchiness from the first wear.
Relying on vibrational sound therapy, SONU gently stimulates the sinuses with acoustic frequencies to relieve congestion, itchiness, and runny nose
SONU uses vibrational sound therapy to help you feel better within minutes. The headband gently yet effectively vibrates the sinuses with acoustic frequencies that are personalized to your specific needs.
This stimulating action minimizes swelling and inflammation, promoting drainage in the process so you can quickly get back to breathing more clearly.
The product is a world apart from traditional allergy treatments, which block the body's histamine reaction responsible for all of those unpleasant symptoms. It can take a while for them to work, and in some cases they may not do the job at all.
Not only does SONU work, but it is clinically proven to be just as effective — if not more effective — as traditional steroid nasal sprays. There's no mess or unpleasant taste involved here, and it can help with even more severe allergic symptoms.
That includes the stuffiness that makes it feel impossible to breathe, the runny nose that makes going about your normal activities feel like a challenge, and the maddening itchiness.
If that has a 'too good to be true' ring to it, you really need to experience it to believe it. According to one user, 'I just started to use this four days ago and had the best night sleep since I can remember. I am a believer. Congestion is much improved.'
It's been so effective, in fact, that more than 80 percent of users experienced a significant drop in their congestion symptoms. They also showed a remarkable 2x improvement in their discomfort compared to a placebo.
What's especially notable is that your therapy is tailored to your needs. To get started, you'll first need to scan your face using the SONU app. The scan reads your features to determine the placement of sinus and nasal cavities for accurate treatment.
Then simply put on the headband (available in your choice of black and gray) and press the button on the front to activate the sound vibrations.
The app even gives you detailed feedback about your success via SONUCheck, which uses AI to analyze your voice and determine how well you are breathing in real time. The score tells you just how open your nasal passages are during your therapy.
Once you try it, you may never look back. 'I am obsessed with my SONU Band,' confessed a shopper. 'I have my husband hooked too. It has made such a difference in my life. I am truly grateful!'
'Amazing,' said a third. 'This device literally helps me breathe. I now sleep better and live better. SONU has saved me thousands of dollars on custom compounded nasal sprays that I no longer need. No more nasal washes. No more decongestants.'
It's also comfortable — another perk that makes the SoundHealth SONU Band well worth it if you're mired by allergies. Get in on this game-changing treatment now and experience the difference for yourself!
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
20 minutes ago
- BBC News
Newcastle University kidney drug research 'may be life-changing'
Early withdrawal of a treatment for people with a rare kidney disease is possible without relapse, safer for patients and saves the NHS millions of pounds, researchers Haemolytic Uraemic Syndrome (aHUS) is a life-threatening condition caused by an uncommon defect in the immune system which, in the past, led to kidney failure.A study by Newcastle University has found most patients can stop taking the drug eculizumab after six months and their disease will not return. Prof Neil Sheerin, who led the study, said the findings had "the potential to significantly change the way we manage aHUS and this may be life-changing for some patients". Ending the use of the drug after six months could lead to NHS savings of £4.2m per patient over their lifetime, the university chiefs previously recommended patients stay on eculizumab for the rest of their lives although that leads to an increased risk of meningococcal sepsis. 'I feel like myself again' Twenty-eight people, aged two to 59, from England and Scotland and who had been on eculizumab for at least six months, took part in the patients had their treatment withdrawn. Only four participants' kidney disease returned and the remaining 24 have remained aHus-free to date, the university those taking part was Louise Percival, of York, who was diagnosed with aHus in 35-year-old said she had suffered several side effects, such as migraines, hair loss and breathlessness, before being taken off eculizumab during the described the findings as fantastic."When I was diagnosed with aHUS I felt overwhelmed as it was a huge burden to live with," she said. "It was life-changing as it's something that will never go away."I strongly disliked the eculizumab infusions as they had to be given religiously every two weeks, which impacted my holidays and social events."I'm a very active person, enjoying hiking and the gym, so the side effects and time needed for the treatment were detrimental to my quality of life."I have a fear of needles, so having a cannula put in my arm every fortnight was very distressing."All of the side effects disappeared and I feel like myself again." Prof Sheerin said when a patient initially started treatment for aHUS "they faced a lifetime of eculizumab and the dangers associated with it"."Now we have shown that many people can stop the treatment, freeing them from the burden of regular intravenous injections and removing risk of serious infection associated with the drug," he said."In addition, significant efficiency savings for the NHS of £110.4m over five years could be realised in this patient population through more targeted use of this high-cost treatment."The study was funded by the National Institute for Health and Care Research and published in The Lancet Regional Health Europe. Follow BBC North East on X, Facebook, Nextdoor and Instagram.
Daily Mail
20 minutes ago
- Daily Mail
Warning issued as Britain's 'most dangerous spider' with 'unbearable' bites invades homes across the UK
A stark warning has been issued as Britain's 'most dangerous spider' with an 'unbearable' bite, is about to invade homes across the UK. False Widow spiders are set to appear in greater numbers as spider mating season is set to begin later on in August. This is prompting experts to urge people to keep windows closed both day and night. The venomous animal delivers a bite that, although not lethal, can cause swelling, painful burns and even fever. It is the largest of the three false widow species commonly found near homes. Dr Tom Elwood said as 'spider season' kicked off this month - when horny males move indoors to search for mates - the eight-legged critters could scuttle through pipes into homes. The arachnologist said: 'August is when male spiders become active - they're searching for a mate and they'll wander through open windows, up walls, into bathtubs - anywhere they can.' It comes after Dr Elwood this week urged Brits to clean their windows to stop grimy, cobwebbed frames becoming a haven for the poisonous arachnids. Dr Elwood encouraged Brits to keep their bathtubs, sinks and other areas of their homes clean and tidy to hold back the invasion of venomous critters. He said: 'Spiders are drawn to dust, insect remains and debris.' He added: 'Spiders are already on the move. You may not see them, but they're out there, climbing walls, slipping in through vents and squeezing through the tiniest cracks.' The noble false widow is 'widely regarded as the most dangerous spider breeding in Britain,' according to a 2020 paper by Clive Hambler, an Oxford University zoologist. Known as Steatoda nobilis, they're not native to Britain and are thought to have arrived from the Canary Islands in banana boxes in the late 1800s before slowly spreading northwards. The Daily Mail previously reported that a man believes he was bitten by this spider left him in 'unbearable' pain and struggling to walk. Keith Robinson, 65, says he developed a large, angry inflammation on his leg shortly after clearing out cobwebs at home. At first, he tried to treat it himself using painkillers and savlon, but before long, it became too much to bear and he went to the hospital. Now he's been diagnosed with cellulitis around the wound, and can only walk for short distances before 'intense pain' sets in. He said: 'It must be more than a coincidence that I had removed a large number of cobwebs from the house by hoover. 'So I'm thinking that I've disturbed a spider, and at some point, I got bitten.' The bite, unnoticeable at first, only got worse as the days passed. ARACHNOPHOBIA IS IN OUR DNA Dating back hundreds of thousands of years, the instinct to avoid arachnids developed as an evolutionary response to a dangerous threat, the academics suggest. It could mean that arachnophobia, one of the most crippling of phobias, represents a finely tuned survival instinct. And it could date back to early human evolution in Africa, where spiders with very strong venom have existed millions of years ago. Study leader Joshua New, of Columbia University in New York, said: 'A number of spider species with potent, vertebrate specific venoms populated Africa long before hominoids and have co-existed there for tens of millions of years.
The Sun
20 minutes ago
- The Sun
Brits fast-tracked onto NHS trial of ‘game-changing' cancer vaccine to combat sex-related cases
PEOPLE with head and neck cancer will be given fast-track access to a new "transformative" cancer jab. The injection targets advanced forms of the devastating disease, giving patients "renewed hope of holding it at bay". 2 It works by boosting the immune system's response by using Covid jab-style mRNA technology helping it 'attack' cancer cells containing human papillomavirus (HPV) proteins. Up to 70 per cent of all head and neck cancers are linked to HPV, a virus often spread via sex. This move adds to the NHS England's Cancer Vaccines Launch Pad programme, which has already helped 550 bowel and skin cancer patients. More than 100 patients with advanced head and neck cancer are expected to benefit from the jab through the AHEAD-MERIT (BNT113) trial, running at 15 hospitals over the next year. Head and neck cancer is a general term to describe forms of the disease in those regions of the body, and can include cancer of the mouth, throat or voice box. Around 11,000 new cases are diagnosed in England every year. HPV is a common virus spread through close contact, including sex and childbirth. Most HPV infections clear naturally without causing symptoms. 'Low-risk' types may cause warts, like genital warts or verrucas on hands and feet. But at least 14 'high-risk' types can sometimes trigger cancer. Rock star devastated as he's diagnosed with 'very aggressive' cancer and shares snap from hospital bed Despite treatment advances, aggressive head and neck cancers remain tough to beat, with high recurrence rates and less than 50 per cent surviving beyond two years. The vaccine used in the study has been designed to create two proteins that are commonly found in head and neck cancers associated with high-risk types of HPV. These types of cancer, known as squamous cell cancers, develop from flat, scale-like cells in the outer layer of the skin and other areas of the body. Health minister Karin Smyth described the plan as a "massive win for cancer patients". She added: "These cancer vaccines could be game-changing for patients facing some of the most challenging diagnoses. "By getting these trials running in our NHS, we're putting ourselves at the forefront of medical innovation, improving outcomes for people living with cancer." NHS England has joined forces with life sciences company BioNTech to help identify potentially eligible patients to refer to NHS hospitals running the trial. 2 The trial is the third to be run through the NHS Cancer Vaccine Launch Pad, which is supported by the Cancer Research UK-funded Southampton Clinical Trials Unit. Professor Peter Johnson, national clinical director for cancer at NHS England, said: "It's fantastic that more patients with advanced head and neck cancers will now be able to access this potentially transformative vaccine, offering renewed hope of holding the disease at bay." Tamara Kahn, chief executive at Oracle Head & Neck Cancer UK, said the trial "offers crucial hope to those living with advanced stages of cancer". "While we advocate for HPV vaccination to prevent these cancers, those already fighting this devastating disease urgently need new treatments that could mean more time with loved ones," she added. 'It'll allow people to get on with their lives' Chris Curtis was diagnosed with HPV-related head and neck cancer in 2011 and set up a support charity, The Swallows. The 67-year-old, from Blackpool, said: "As a survivor of HPV-related head and neck cancer, I know first-hand the physical, emotional, and psychological toll this disease takes not just on the patient, but on the entire support system around them. "With this aggressive cancer you live in the fear of reoccurrence every day - so anything that could help control the disease or give people peace of mind is groundbreaking - it'll allow people to get on with their lives and move forward." The Cancer Vaccine Launch Pad - a partnership between NHS England, the Government and BioNTech - has already helped refer about 550 patients to trials for vaccines for bowel and skin cancers. Dr Iain Foulkes, executive director of research and innovation at Cancer Research UK, said: "The Cancer Vaccines Launch Pad is an important route to fast-track promising mRNA vaccine technology into clinical trials. "Research into personalised cancer treatments is vital. "There are over 200 different types of cancer and it's unlikely there will ever be a single cure that works for everyone. "That's why it's vital that we support a wide range of research, so that more people can live longer, better lives, free from the fear of cancer."
